BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Expected to Announce Quarterly Sales of $4.54 Million

Brokerages expect that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will post $4.54 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for BioCryst Pharmaceuticals’ earnings. The highest sales estimate is $7.14 million and the lowest is $1.07 million. BioCryst Pharmaceuticals posted sales of $1.45 million in the same quarter last year, which suggests a positive year over year growth rate of 213.1%. The business is scheduled to issue its next quarterly earnings results on Tuesday, November 5th.

According to Zacks, analysts expect that BioCryst Pharmaceuticals will report full year sales of $13.93 million for the current year, with estimates ranging from $10.47 million to $16.34 million. For the next financial year, analysts forecast that the firm will report sales of $39.43 million, with estimates ranging from $10.00 million to $87.44 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.03). The company had revenue of $1.45 million for the quarter, compared to analyst estimates of $2.52 million. BioCryst Pharmaceuticals had a negative return on equity of 371.33% and a negative net margin of 1,091.44%.

BCRX has been the topic of several analyst reports. BidaskClub cut BioCryst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, October 4th. Zacks Investment Research cut BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, August 8th. Finally, ValuEngine upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. BioCryst Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $9.08.

BCRX opened at $2.45 on Friday. BioCryst Pharmaceuticals has a 12 month low of $2.35 and a 12 month high of $9.95. The company has a debt-to-equity ratio of 2.38, a current ratio of 1.44 and a quick ratio of 1.43. The stock has a market cap of $262.84 million, a P/E ratio of -2.49 and a beta of 1.95. The stock’s 50 day moving average price is $2.89 and its 200 day moving average price is $4.56.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. UBS Group AG boosted its stake in BioCryst Pharmaceuticals by 331.0% during the 2nd quarter. UBS Group AG now owns 2,202,794 shares of the biotechnology company’s stock valued at $8,349,000 after purchasing an additional 1,691,681 shares in the last quarter. University of Notre Dame DU Lac bought a new position in BioCryst Pharmaceuticals during the 2nd quarter valued at $1,854,000. Voloridge Investment Management LLC boosted its stake in BioCryst Pharmaceuticals by 942.0% during the 2nd quarter. Voloridge Investment Management LLC now owns 130,300 shares of the biotechnology company’s stock valued at $494,000 after purchasing an additional 117,795 shares in the last quarter. Nuveen Asset Management LLC bought a new position in BioCryst Pharmaceuticals during the 2nd quarter valued at $3,101,000. Finally, UBS Asset Management Americas Inc. boosted its stake in BioCryst Pharmaceuticals by 7.9% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 65,958 shares of the biotechnology company’s stock valued at $250,000 after purchasing an additional 4,803 shares in the last quarter. 90.73% of the stock is owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Read More: What is a dividend reinvestment plan?

Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.